暗盘资金正涌入这些股票，点击速看>>> 创新药概念股震荡走强，迈威生物20cm涨停，华人健康（301408）、锦波生物涨超10%，昂利康 （002940）涨停，舒泰神（300204）、康龙化成（300759）跟涨。消息面上，国家医疗保障局近日印发 《2025年基本医保目录及商保创新药目录调整申报操作指南》，首次将商业健康保险创新药目录纳入调 整方案。 ...

Group 1 - The core point of the news is the significant rise in stock prices of companies like Loongson Technology and Kanglong Chemical, attributed to the launch of new domestic CPUs [1][3] - Loongson Technology released the Loongson 3C6000 series server processors and other chips at the 2025 product launch event, emphasizing their "fully autonomous" design without reliance on foreign technology [3] - The Loongson 3C6000 chip is expected to be applied in critical fields that require high security, highlighting the importance of domestic technology in these sectors [3] Group 2 - The Double Innovation Leader ETF (588330) is actively trading, with a price increase of 0.72% and a transaction volume exceeding 30 million yuan, indicating strong market interest [1][3] - The ETF tracks the Sci-Tech Innovation and Entrepreneurship 50 Index, which includes 50 large-cap companies from the Sci-Tech and Growth Enterprise markets, covering sectors like new energy and semiconductors [3] - The ETF provides a low-threshold investment opportunity for accessing multi-layered capital markets, positioning it as a potential "rebound leader" in the market [3]

Core Viewpoint - The article discusses the performance and holdings of the China Europe Medical Innovation Stock C fund, highlighting its recent net value, returns, and top stock holdings [1]. Fund Performance - The latest net value of China Europe Medical Innovation Stock C is 1.2877 yuan, reflecting a decrease of 1.98% - The fund has achieved a return of 7.99% over the past month, ranking 75 out of 793 in its category - Over the last six months, the fund's return is 27.89%, ranking 30 out of 775 - Year-to-date, the fund has returned 29.77%, ranking 26 out of 775 [1]. Fund Holdings - The top ten stock holdings of the fund account for a total of 75.62%, with the following key positions: - WuXi AppTec (10.35%) - Kelun-Biotech (10.15%) - WuXi Biologics (9.82%) - WuXi AppTec (9.60%) - CanSino Biologics (7.89%) - Hangzhou Tigermed Consulting (7.01%) - Hengrui Medicine (6.20%) - Kintor Pharmaceutical (5.87%) - Baillie Gifford (4.70%) - Tigermed (4.03%) [1]. Fund Background - China Europe Medical Innovation Stock C was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 3.524 billion yuan - The fund manager is Ms. Ge Lan, who has extensive experience in the investment management field [1][2].

Group 1 - The core viewpoint of the article highlights the performance and holdings of the GF Healthcare Stock A fund, which has a recent net value of 1.8514 yuan and a decline of 0.89% [1] - The fund's performance over the past month shows a return of 3.13%, ranking 594 out of 1027 in its category; over the past six months, it has returned 13.87%, ranking 139 out of 995; and since the beginning of the year, it has achieved a return of 14.54%, ranking 139 out of 997 [1] - The top ten holdings of the GF Healthcare Stock A fund account for a total of 48.15%, with significant positions in companies such as Zai Lab (10.52%), Kelun Pharmaceutical (8.39%), and others [1] Group 2 - The GF Healthcare Stock A fund was established on August 10, 2017, and as of March 31, 2025, it has a total scale of 5.237 billion yuan [1] - The fund manager, Wu Xingwu, has extensive experience in the investment management field, having held various positions in different funds and companies since 2015 [2]

最新一期业绩显示，2025年一季报，公司实现营业收入5.66亿元，同比58.96%；净利润1.53亿元，同比 130.10%，销售毛利率70.20%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)3诺泰生物24.1229.264.31118.34亿行业平均 39.5845.743.43155.97亿行业中值40.6052.662.7056.52亿1药明康德16.8719.963.031886.47亿2康龙化成 22.1623.082.95413.96亿4普蕊斯25.9622.232.0023.66亿5诺禾致源27.7928.722.2356.52亿6凯莱英 30.0031.411.73298.03亿7诺思格30.4831.132.3443.65亿8爱尔眼科31.1532.475.291154.48亿9华康洁净 35.1736.811.4224.59亿10通策医疗35.5236.294.32181.96亿11昭衍新药36.72192.041.75142.25亿12华厦眼科 37.7437.192.70159.43亿 来源：金融界 6月26日，诺泰生物今日收盘37.59元，下跌1.57%，滚动市盈率PE ...

一、股东股份质押及解除质押的基本情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）近日接到公 司实际控制人楼小强先生的函告，获悉楼小强先生将其所持有的公司部分股份进 行了质押和解除质押，具体情况如下： 证券代码：300759 证券简称：康龙化成 公告编号：2025-034 康龙化成（北京）新药技术股份有限公司 关于公司实际控制人股份质押和解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 注：截至本公告日，公司已完成 2021 年 A 股限制性股票激励计划第三个归属期和 2022 年 A 股限制性股票激励计划第二个归属期归属，归属完成后公司总股本由 1,777,786,009 股增 至 1,778,195,525 股。截至目前，上述工商变更登记手续尚未全部完成，本公告中占公司总 股本比例以 1,778,195,525 股为计算基数。 上述质押股份不负担重大资产重组等业绩补偿义务，对公司的生产经营、公 司治理不会产生重大影响，实际控制人亦将积极防范风险。 股东 名称 是否为控股 股东或第一 大股东及其 一致行动人 本次质押 数量 （股） ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-035 康龙化成（北京）新药技术股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"本公司"）2024 年年 度利润分配方案已获 2025 年 6 月 20 日召开的 2024 年年度股东大会（以下简称 "股东大会"）审议通过，现将本公司 A 股利润分配事宜公告如下，H 股股东的 利润分配实施情况不适用本公告，H 股股东的利润分配安排请参见本公司于香港 联合交易所有限公司及本公司网站发布的相关公告。 2、本次利润分配方案披露至实施期间本公司股本总额及 H 股库存股数量未 发生变化。 3、本次实施的利润分配方案与股东大会审议通过的分配方案一致。 4、本次实施的利润分配方案距离股东大会审议通过的时间未超过两个月。 二、利润分配方案 本公司 2024 年年度利润分配方案为：以本公司现有 A 股总股本剔除已回购 股份 0 股后的 1,476,658,400 股为基数，向全体股东每 10 股派 2.000000 元人 ...

简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日)。现任中欧医疗健康混合型证券投资基金基金经理(自2016年9 月29日起至今),中欧明睿新起点混合型证券投资基金基金经理(自2018年7月12日起至今)、中欧阿尔法混 合型证券投资基金基金经理(2020年8月20日起至2023年9月28日)。 来源：金融界 金融界2025年6月23日消息，中欧医疗健康混合A(003095) 最新净值1.6675元，增长1.10%。该基金近1个 月收益率1.79%，同类排名725|2535；近3个月收益率5.36%，同类 ...

金融界2025年6月23日消息，中欧医疗创新股票A(006228) 最新净值1.3629元，增长2.04%。该基金近1个 月收益率6.36%，同类排名28|561；近6个月收益率28.48%，同类排名18|548；今年来收益率31.07%，同 类排名17|550。 中欧医疗创新股票A股票持仓前十占比合计75.62%，分别为：药明合联（10.35%）、科伦博泰生 （10.15%）、药明生物（9.82%）、药明康德（9.60%）、康方生物（7.89%）、康龙化成（7.01%）、 恒瑞医药（6.20%）、凯莱英（5.87%）、百利天恒（4.70%）、泰格医药（4.03%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年3月31日，中欧医疗创新股 票A规模46.75亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 ...

Summary of Conference Call Records Industry Overview - The pharmaceutical sector, particularly the innovative drug segment, remains a core focus despite recent adjustments, which may present entry opportunities [1][2] - The industry is benefiting from overseas expansion and positive data from high-quality drugs, with expectations for continued growth over the next two to three years [1][2] - The Hong Kong innovation index shows significant room for growth compared to its peak in 2021, currently at historical median levels [1][2] Key Catalysts for Future Growth - Upcoming catalysts include: - June: R&D Day for BeiGene and other leading companies - August: Mid-year performance reports - September: World Lung Cancer Conference (WCLC) - October: American Society of Clinical Oncology (ASCO) meeting - December: American Society of Hematology (ASH) annual meeting - Adjustments in the medical insurance catalog and collaboration with commercial insurance are also noteworthy developments [4] Recommended Companies - Top recommendations include BeiGene, which is currently undervalued in the Hong Kong market, and Heng Rui Medicine [5] - Mid-cap companies to watch include Innovent, CSPC, and Kangfang, with potential for over 30% growth [5] - Small-cap companies with pipeline value reassessment logic are also highlighted, including Yifang Bio and Dize Pharmaceutical in A-shares, and Yuanda Pharmaceutical in Hong Kong [6] Performance Expectations - Companies in the innovative drug supply chain, such as WuXi AppTec, Kelun Pharmaceutical, and Kanglong Chemical, are expected to maintain strong performance in their mid-year reports [7] - CXO companies like Tigermed and Zhaoyan New Drug are seeing good order trends, although a rapid recovery in performance may not be immediate [7] Life Sciences Sector - Life sciences upstream companies have seen stock price adjustments but are showing early signs of recovery, with revenue growth guidance generally above 15% for the year [8] - Companies like WuXi AppTec, Haoyuan, and Bide are noted for their strong fundamentals and potential for mergers and acquisitions [8] Potential Recovery Areas - The medical device, OTC, and consumer sectors may show signs of recovery in the second half of the year, with some companies already indicating marginal improvements [9] PROTAC Technology Insights - PROTAC technology is recognized for its potential to address challenges in small molecule drug development, particularly in targeting hard-to-drug proteins [3][10] - The technology has shown promise in treating blood diseases, with BeiGene's BTK PROTAC entering Phase III clinical trials [18] - PROTAC's advantages include the ability to degrade multiple target proteins and improved selectivity, which may reduce toxicity compared to traditional small molecules [12][14] Clinical Research and Development - Clinical studies are demonstrating PROTAC's advantages over traditional small molecules in various therapeutic areas, including oncology and autoimmune diseases [15][24] - Companies like BeiGene are leading in the development of PROTAC platforms, with several products in advanced clinical stages [25] Challenges and Risks - The development of PROTAC technology faces challenges, including the need for sophisticated molecular design capabilities and potential competition among small molecules [17][30] - The market for AR PROTAC in prostate cancer is limited due to existing competition and established treatment standards [22] Conclusion - The innovative drug sector, particularly through the lens of PROTAC technology, presents significant investment opportunities despite current market adjustments. Companies with strong pipelines and upcoming catalysts are positioned for potential growth in the coming years [1][4][5][25]